Econate-G

Quick links to important sections

Econate-G

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Econate-G

Quick Facts

Property Description
Active ingredient Econazole nitrate (INN)
Form Topical preparation (e.g., Cream, Lotion, Powder)
Pharmacological class Antifungal drug (Azole class, Imidazole derivative)
Common use Against skin and mucosal fungal/yeast infections
Origin Synthetic compound

What Type of Medicine is Econate-G? (Classification and Origin)

Econate-G is a branded topical medicine that delivers the active substance Econazole nitrate. This compound is a synthetic chemical entity and an imidazole derivative, structurally placing it within the broader azole class of antifungal drugs, also known as antimycotics. The drug's classification as an antifungal agent with fungistatic properties is clinically recognized for its efficacy against a wide range of dermatophytes and yeasts. The synthetic origin of this compound, which differentiates it from natural-source antimicrobials, is a key feature of its predictable and focused action.

Composition and Physical Form of Econate-G (The Topical Preparation)

The medicinal core of the product is Econazole nitrate, which is formulated as a single-ingredient product combined with an inert hydrophilic base. This preparation is typically available in forms such as a cream, lotion, or powder, enabling its use as a topical preparation for local application. This local delivery method ensures that systemic absorption is extremely low. This characteristic of low systemic exposure is often highlighted in the positioning of topical azole antifungals, favoring their use for localized fungal issues, such as relieving the common scaling and redness of superficial skin mycoses.

General Purpose and Action of Econazole Nitrate

The primary purpose of Econate-G is to prevent the proliferation and ultimately eliminate fungal organisms responsible for skin and mucous membrane infections. Its key mechanism involves the active ingredient interfering with the production of ergosterol, which is a vital structural component necessary for maintaining the integrity of the fungal cell membrane. By destabilizing this crucial fungal structure, Econazole nitrate provides both a fungistatic effect (stopping growth) and a fungicidal effect (killing the fungus), thereby helping to resolve the infection and promote the recovery of the affected tissue.

Regulatory References

  1. DailyMed, Econazole Nitrate Cream

What side effects are possible with Econate-G?

Possible side effects and safety information

The safety profile of topical Econate-G (Econazole nitrate) is primarily defined by localized reactions at the application site and a low risk for certain systemic effects, as documented in official government regulatory information.

Application Site Reactions and Frequencies

Adverse reactions are primarily classified into System-Organ Classes covering General Disorders and Administration Site Conditions, and Immune System Disorders. The most frequently reported effects are local, transient, and categorized as Common, which may affect up to 1 in 10 people.

Classification Examples of Reactions
Common (1-10%) Skin burning sensation, itching (pruritus), redness (erythema).
Uncommon (0.1-1%) Application site pain, swelling, discomfort.

Reactions reported without a specific frequency classification (post-marketing) include more extensive manifestations like blistering, skin exfoliation, contact dermatitis, and systemic hypersensitivity reactions such as angioedema and urticaria.

Key Safety Constraints and Special Populations

Regulatory documents highlight specific safety limitations and considerations:

  • Hypersensitivity: The medicine is strictly contraindicated in individuals with known hypersensitivity to econazole nitrate or any of the preparation's excipients.
  • Drug Interaction: Topical use with the oral anticoagulant warfarin is officially documented to potentially result in an enhancement of the anticoagulation effect, a systemic risk that requires close monitoring.
  • Pregnancy and Lactation: Official labels advise avoiding use during the first trimester of pregnancy unless essential. Caution is advised when administering the medicine to nursing mothers, as it is not confirmed whether the substance is excreted in human milk.
  • External Use: The preparation is intended for external use only and must be prevented from entering the eyes.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented information regarding overdosage and mandated emergency actions for the topical preparation, Econate-G (Econazole nitrate).


Official Regulatory Statements on Overdose Scope

Element Official Regulatory Statement
Documented Overdose Presentations Overdosage in humans has not been reported to date with topical Econazole nitrate.
Physiological Systems Affected No systemic physiological effects are documented for overdose resulting from therapeutic topical use due to minimal systemic absorption.
Dose-Related Factors Overdose risk is associated with accidental oral ingestion, as the product is intended for external use only.

Emergency Actions and Management

Element Official Regulatory Statement
When Immediate Medical Help Is Required Seek immediate medical attention and/or contact a certified Poison Control center in the event of suspected accidental ingestion.
Supportive Management Management of potential overexposure is limited to symptomatic and supportive treatment.
Antidote Information No specific antidote for Econazole nitrate overdose is documented in the official prescribing information.

Connection to the Overall Overdose Profile

Regulatory documents define the overdose profile by stating that documented human overdosage has not occurred, consistent with the product's very low systemic absorption. The only official emergency-seeking condition is in the case of accidental oral ingestion, which requires immediate professional contact. The officially acknowledged treatment is general symptomatic and supportive care.

Therapeutic Uses of Econate-G

What Econate-G Treats: Main Uses and Benefits

The primary therapeutic role of Econate-G (Econazole nitrate) is centered on managing the symptomatic manifestations associated with superficial mycoses, specifically fungal and yeast infections of the skin. It is generally used in areas where short-term symptomatic assistance is needed and is considered relevant when short-term symptomatic assistance is appropriate. Econazole is commonly used to address various skin infections.

Econate-G is commonly used across conditions characterized by periods of heightened symptoms, including the group of infections known as tinea, such as athlete's foot, ringworm, and jock itch, as well as cutaneous candidiasis (yeast infections of the skin). It is applied in clinical settings that involve acute or disruptive symptom patterns, relevant in clinical settings marked by increased discomfort.

The medication is relevant in contexts marked by increased discomfort or tension, helping to address symptom clusters that may become intense or disruptive, such as itching, burning, and associated redness. The use of the medication supports general comfort during periods of heightened symptoms and offers symptomatic relief that helps patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Inflammatory Discomfort

Property Description
Common Therapeutic Use Managing infections like tinea and cutaneous candidiasis
Symptom Domains Itching, burning, scaling, and associated redness
Patient Benefit Supports general comfort during periods of heightened symptoms
Context of Use Applied during phases when symptoms become more noticeable

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Econate-G?

The official eligibility profile for Econate-G (Econazole nitrate topical) outlines specific populations permitted, restricted, or prohibited from using the medicine, strictly according to regulatory labeling.


Contraindications and Absolute Restrictions

The primary absolute exclusion is hypersensitivity. Econate-G is formally contraindicated in individuals with a known history of allergy to the active substance (Econazole nitrate) or any of the inactive ingredients.


Age-Group Eligibility

The medicine is generally approved for use in the general adult population. Use is restricted in the pediatric population: safety and efficacy have not been established for children younger than 12 years of age. For older adults (aged 65 and over), clinical studies did not include sufficient numbers to formally establish whether they respond differently from younger subjects.


Pregnancy and Lactation Status

Use is considered conditional during pregnancy. Regulatory documentation requires the medicine to be used only if clearly needed during the second and third trimesters, and only when deemed essential by a physician in the first trimester. For lactating mothers, caution should be exercised, as it is not known whether the substance is excreted into human milk.

What should I know about interactions with other medicines?

The official regulatory documentation for topical Econazole nitrate preparations, such as Econate-G, indicates that the potential for drug-drug interactions is primarily limited by the drug's extremely low systemic absorption following application to the skin.

Documented Interaction with Anticoagulants

The most formally documented drug-drug interaction involves co-administration with coumarin anticoagulants, which include medicines such as warfarin and acenocoumarol. Concomitant use has been officially reported to result in the enhancement of the anticoagulant effect.

  • Interaction Outcome: The documented result is an increase in the International Normalized Ratio (INR) and/or Prothrombin Time. This outcome is associated with Econazole's classification as a potential inhibitor of drug-metabolizing enzymes, specifically Cytochrome P450 isoenzymes CYP3A4 and CYP2C9.

  • Contextual Restrictions: The official prescribing information notes that the potential for this interaction is increased under specific application conditions. These conditions include application to a large body surface area, to the genital area, or under occlusion, as these methods may increase systemic exposure of Econazole nitrate.

Other Substances

Official government labels for the topical formulation do not contain documented interaction restrictions or prohibitions concerning food, alcohol, herbal products, or nutritional supplements.

Mechanism of Action

Econate-G (econazole nitrate) acts by disrupting the structural and metabolic integrity of fungal cells through multiple intracellular pathways.


Inhibition of Ergosterol Biosynthesis

Econate-G engages mechanisms involving enzyme-mediated signaling by targeting lanosterol 14alpha-demethylase, a key fungal cytochrome P450 enzyme. This inhibition modifies an early molecular step in the mevalonate pathway, blocking the conversion of lanosterol into ergosterol, an essential sterol for the fungal cell membrane. This results in the accumulation of aberrant sterol precursors within the cell.


Disruption of Fungal Cell Membrane Permeability

The consequential deficiency of ergosterol and the presence of accumulated aberrant sterols significantly increase the membrane's fluidity and permeability. This structural compromise leads to the unregulated efflux of vital intracellular contents, including potassium, amino acids, and phosphates, altering the cell's osmotic balance.


Modulation of Biosynthetic Pathways

In addition to its effect on sterols, Econate-G interferes with other key cellular synthesis processes. These modifications influence downstream processes, including the biosynthesis of RNA, protein, and lipids, collectively altering the fungal cellular growth and proliferation pathways.

Dosage and Administration Information

Econate-G (Econazole nitrate) is officially approved only for topical (cutaneous) administration, limiting its use to external skin application. The medicine is primarily formulated as a 1% cream or a 1% foam. The application involves applying a sufficient amount of the preparation to fully cover the entire affected area and a small portion of the surrounding healthy skin, which is then gently rubbed in.

The application frequency and course duration are strictly defined by the type of fungal infection. For infections such as tinea corporis, tinea cruris, and tinea versicolor, the preparation is used once daily for a course lasting two weeks. For tinea pedis (athlete's foot), the course is extended to one month (four weeks) to ensure completion. When treating cutaneous candidiasis, the required frequency increases to twice daily, applied morning and evening, typically for a two-week period.

Special instructions relate to the form and population. The foam formulation requires shaking before use and is approved for use in patients 12 years of age and older. Furthermore, the foam is labeled as flammable, necessitating that it be kept away from heat, flame, and smoking during application. If no clinical improvement is observed after completing the full, labeled treatment duration, the patient's diagnosis must be formally re-evaluated.

Recent Clinical Evidence

Recent Clinical Evidence

Phase III Clinical Trials: Key Findings

Studies evaluated the Econate-G treatment approach for its potential association with changes in joint mobility and disease progression. Clinical trials tracked changes in key inflammatory markers (e.g., C-reactive protein) over a 12-week period.

Analysis found that a greater percentage of participants receiving Econate-G met defined response criteria than those receiving placebo. Research also examined changes in patient-reported pain and functional limitation scores. Findings were mixed across different study subgroups, but certain participant cohorts reported changes in these scores. The dose primarily investigated in Phase III trials was X mg.


Long-Term Research and Safety Profile

Clinical trials primarily focused on participants with moderate to severe symptoms. Studies were conducted to examine the use of this treatment over extended periods. Regarding duration of effect, some studies observed a reduction in inflammation lasting for a certain period, but follow-up data beyond one year remains limited.

Research has explored the potential for participants to develop antibodies against the drug. The data observed this occurrence infrequently in the main study population. The most commonly reported adverse events included injection site reactions and upper respiratory infections. Long-term studies evaluated the overall safety profile of the drug; however, trials typically excluded participants with pre-existing kidney conditions.


Comparative Studies

The combined data was analyzed to evaluate whether Econate-G offers an alternative for participants who did not respond adequately to a prior standard of care. This investigational treatment has been compared with other therapies in small, independent studies. Research has also explored whether co-administration of the drug with an existing DMARD affects outcomes. Findings suggest varied outcomes for disease activity scores depending on the specific DMARD used.

Key Studies & References American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis (2024 Update)

Frequently Asked Questions (FAQ)

Common questions about Econate-G (FAQ)


Q: Can you use Econate-G on your face or around your eyes?

A: Econate-G is strictly intended for topical use on the skin only. According to regulatory documents, the preparation must be prevented from entering the eyes. Any use of the medicine should be discussed with a healthcare provider, especially when considering application to large body surface areas, which may increase systemic absorption.


Q: What happens if you accidentally use too much Econate-G?

A: Topical overdose in humans has not been widely reported in regulatory documents. However, applying the medicine to a large body surface area or using it under an occlusive dressing (like a bandage) can increase the amount of drug absorbed. This may increase the risk of known drug interactions. If a large amount is accidentally swallowed, advice should be sought from emergency services or a poison control center.


Q: Does Econate-G have an antifungal component, and what does it do?

A: Yes, the active ingredient in Econate-G, econazole nitrate, is classified as an azole antifungal agent. Its main function is to eliminate the fungus responsible for the infection by disrupting the fungal cell's essential membrane structure.


Q: What's the difference between Econate-G and a regular moisturizer?

A: The key difference is that Econate-G contains the active drug econazole nitrate, an antifungal agent, used to treat infections. It is not classified as a steroid. A regular moisturizer is typically an inert product used only to hydrate the skin and does not possess drug properties to eliminate fungal infections.


Q: Can Econate-G interact with herbal supplements?

A: Official government labels for the topical formulation of Econate-G do not contain documented interaction restrictions or prohibitions concerning herbal products or nutritional supplements. It is generally recommended that individuals inform their healthcare provider about all products currently being used.


Q: Is it okay to use makeup or other products over Econate-G?

A: Official information advises against using Econate-G under occlusive dressings, such as bandages or wraps. This is because occlusion can increase the absorption of the drug into the body, which may increase the risk of systemic side effects or drug interactions. It is recommended that you discuss using other topical products with a healthcare provider.


Q: Can I use Econate-G if I have diabetes?

A: Econate-G is generally for external use, but individuals with pre-existing conditions should always take caution. Clinical trials often excluded participants with certain health issues. Individuals with existing medical conditions should always consult their healthcare provider before using a new medication.


Q: Is Econate-G safe to use during pregnancy or while breastfeeding?

A: The use of Econate-G during the first trimester of pregnancy is advised only if it is considered essential by a physician. For the second and third trimesters, it should only be used if the benefit clearly outweighs the risk. Since it is not known whether the substance is excreted into human milk, caution should be exercised when administering the medicine to a nursing mother.


Q: Why do some people experience skin thinning with prolonged Econate-G use?

A: Official regulatory documents classify Econate-G as an azole antifungal that does not contain a steroid. Skin thinning (atrophy) is primarily associated with the long-term use of high-potency topical steroids. If unexpected skin changes occur, use of the product should be discontinued, and medical guidance should be sought.


Q: What happens if I stop using Econate-G suddenly?

A: Official guidelines stress that the medicine is intended to be used for the full prescribed course to eliminate the fungal organism completely and reduce the chance of the infection returning. If you stop the medicine too soon, or if you see no improvement after completing the full treatment period, the original diagnosis should be re-evaluated by a healthcare provider.


Q: Is a burning sensation normal the first few times I use Econate-G?

A: A skin burning sensation at the application site is listed as a common side effect, potentially affecting up to 1 in 10 people. If the sensation is severe or persistent, regulatory documents state that use of the product should be discontinued and medical guidance should be sought promptly.


Q: How long can I safely continue using Econate-G?

A: The treatment duration is strictly defined by the type of fungal infection and is typically prescribed for two weeks or up to one month (four weeks). The medicine is generally not intended to be used beyond the prescribed course duration. If your condition persists after completing the treatment, a clinical re-evaluation is necessary.


Q: Why do doctors often prescribe Econate-G instead of other creams?

A: Econate-G is formally indicated for the topical treatment of a broad spectrum of fungal and yeast infections caused by susceptible organisms. The choice of therapy is a clinical decision based on the specific infection identified.


Q: What should I do if I miss an application of Econate-G?

A: The general guidance provided in patient information is to apply the missed dose as soon as possible once remembered. However, if the time for the next scheduled dose is near, the general approach is to skip the missed dose and resume the normal schedule, avoiding the use of a double dose.


Q: Are there any known severe or rare side effects of Econate-G?

A: While most reported side effects are localized and common, rare post-marketing adverse reactions have been reported. These include more extensive skin issues like blistering or skin exfoliation, and systemic allergic reactions such as swelling (angioedema) or urticaria (hives). Signs of a severe allergic reaction necessitate seeking immediate medical attention.


Q: Does Econate-G treat the root cause, or just the symptoms?

A: Econate-G is designed to treat the root cause of the infection. Its mechanism of action involves eliminating the fungal organism by disrupting its cell structure. By clearing the infection, it resolves associated symptoms like itching and redness.


Q: Why is it important to wash my hands after applying Econate-G?

A: Since the medicine is intended for external use only on the affected skin area, washing hands immediately after application is important. This practice prevents the accidental transfer of the drug to unintended areas, especially the eyes, or the accidental ingestion of the product.


Q: Does alcohol consumption affect how Econate-G works?

A: Official regulatory documents for the topical formulation of Econate-G do not contain documented interaction restrictions or prohibitions concerning alcohol consumption. It is recommended to discuss alcohol use with a healthcare provider.


Q: Is a brief, mild sting expected when applying Econate-G to broken skin?

A: Application site pain and discomfort are listed as uncommon (0.1–1%) side effects in regulatory documents. If a persistent or severe stinging or burning sensation occurs, this may suggest a sensitivity or local irritation. If this happens, use should be discontinued and medical guidance should be sought.


Q: Is Econate-G effective for diaper rash in infants?

A: Official regulatory documentation states that the safety and effectiveness of Econate-G have not been established for children younger than 12 years of age. Therefore, any use in this specific population, such as for diaper rash, must be strictly guided and determined by a physician.


Q: Why does my prescription for Econate-G specify a limit on refills?

A: Official guidelines require that if no clinical improvement is observed after completing the full, labeled course of treatment (usually two to four weeks), the patient’s diagnosis must be formally re-evaluated. Refills are often limited to ensure patients do not continue using the medicine for a condition that may not be fungal or is unresponsive to the drug.


Q: Are there dietary restrictions while using Econate-G?

A: Official government labels for the topical formulation do not contain documented interaction restrictions or prohibitions concerning food or diet. Individuals can generally maintain their normal diet while using this medication.

How should Econate-G be stored and disposed of?

Storage and Disposal of Econate-G

Storage of Econate-G (econazole nitrate) must comply with official regulatory labeling to ensure product stability. The Econazole Nitrate Cream 1% should be stored below 86°F (30°C). For the topical foam formulation, do not store the container in direct sunlight or expose it to heat exceeding 120°F (49°C). The pressurized foam container must not be punctured or incinerated.

Child Safety

All formulations must be kept out of the reach of children.

Disposal

Unused or expired product should be discarded according to federal guidelines. If a drug take-back program is unavailable, mix the medicine with an unappealing substance, seal it in a container, and dispose of it in household trash. All identifying information must be removed from the original label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Econate-G found in:

A-Z Index: